Clinical trial
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult…
NCT00231413 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00231413 |
|---|---|
| Title | Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine. |
| Official title | A Dose-range Study to Assess the Safety and Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-month) in Healthy Adult Females (18-25 Years of Age) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | HPV 16/18 L1 AS04, HPV-16/18/31/45 L1 AS04 Formulation 1, HPV-16/18/31/45 L1 AS04 Formulation 2, HPV-16/18/31/45 L1 AS04 Formulation 3, HPV-16/18/31/45 L1 AS04 Formulation 4, HPV-16/18/31/45 L1 AS04 Formulation 5, HPV-16/18/31/45 L1 AS04 Formulation 6 |
| Enrollment | 383 |
| Start date | Mar 4, 2005 |
| Primary completion | Mar 27, 2006 |
| Completion | Mar 27, 2006 |
| First posted | Oct 4, 2005 |
| Last update posted | Dec 12, 2019 |
| Countries | Belgium, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: